Mylan NV (MYL)

34.92
NASDAQ : Health Technology
Prev Close 35.14
Day Low/High 34.72 / 35.45
52 Wk Low/High 30.33 / 47.82
Avg Volume 4.76M
Exchange NASDAQ
Shares Outstanding 515.63M
Market Cap 18.12B
EPS 1.30
P/E Ratio 33.79
Div & Yield N.A. (N.A)

Latest News

Dropbox, Teva Pharmaceuticals, Salesforce: 'Mad Money' Lightning Round

Dropbox, Teva Pharmaceuticals, Salesforce: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Dropbox, Teva Pharmaceuticals, Salesforce, Linde, iQiyi and more.

Theravance Biopharma And Mylan Receive FDA Approval For YUPELRI™ (revefenacin) In Adults With Chronic Obstructive Pulmonary Disease

Theravance Biopharma And Mylan Receive FDA Approval For YUPELRI™ (revefenacin) In Adults With Chronic Obstructive Pulmonary Disease

YUPELRI (revefenacin) is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US

Mylan Moves Up In Analyst Rankings, Passing TechnipFMC

Mylan Moves Up In Analyst Rankings, Passing TechnipFMC

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Mylan NV has taken over the #180 spot from TechnipFMC plc , according to ETF Channel. Below is a chart of Mylan NV versus TechnipFMC plc plotting their respective rank within the S&P 500 over time (MYL plotted in blue; FTI plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Mylan Shares Soar After Drugmaker's Earnings Top Forecasts

Mylan Shares Soar After Drugmaker's Earnings Top Forecasts

Shares of generic drugmaker Mylan soar after adjusted earnings top analysts' forecasts.

Mylan Reports Third Quarter 2018 Results And Reaffirms 2018 Guidance

Mylan Reports Third Quarter 2018 Results And Reaffirms 2018 Guidance

HERTFORDSHIRE, England and PITTSBURGH, Nov. 5, 2018 /PRNewswire/ -- Mylan N.

Amazon, Warren Buffett and 'Bohemian Rhapsody' - 5 Things You Must Know

Amazon, Warren Buffett and 'Bohemian Rhapsody' - 5 Things You Must Know

U.S. stock futures are lower on Monday, as stronger-than-expected U.S. jobs data reignites bets on faster Federal Reserve rate hikes and as investors look ahead to the midterm elections on Tuesday; Amazon reportedly has held advanced talks about establishing its second headquarters in Crystal City, Virginia; 'Bohemian Rhapsody' makes $50 million in its opening weekend.

4 Scenarios That Will Impact the Market: Market Recon

4 Scenarios That Will Impact the Market: Market Recon

And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.

Mylan Launches Hulio™ (Biosimilar Adalimumab) In Markets Across Europe

Mylan Launches Hulio™ (Biosimilar Adalimumab) In Markets Across Europe

HERTFORDSHIRE, England and PITTSBURGH, Oct. 19, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan And Biocon Announce Positive CHMP Opinion For Ogivri®, Biosimilar Trastuzumab

Mylan And Biocon Announce Positive CHMP Opinion For Ogivri®, Biosimilar Trastuzumab

HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 /PRNewswire/ --  Mylan N.

Mylan Adds To Women's Healthcare Portfolio With Launch Of Generic Depo-Provera® Injection

Mylan Adds To Women's Healthcare Portfolio With Launch Of Generic Depo-Provera® Injection

- Mylan's Medroxyprogesterone Acetate Injection is indicated for the prevention of pregnancy-

Mylan To Release Third Quarter 2018 Financial Results On November 5, 2018

Mylan To Release Third Quarter 2018 Financial Results On November 5, 2018

HERTFORDSHIRE, England and PITTSBURGH, Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Prevails In Copaxone® 40mg/mL Litigation Against Teva In U.S. Appellate Court

Mylan Prevails In Copaxone® 40mg/mL Litigation Against Teva In U.S. Appellate Court

Court Affirms Prior Decisions Finding Copaxone® 40 mg/mL Patents Invalid

Theravance Biopharma And Mylan Report Positive New Data From Multiple Studies Of YUPELRI™ (revefenacin) At The 2018 CHEST Annual Meeting

Theravance Biopharma And Mylan Report Positive New Data From Multiple Studies Of YUPELRI™ (revefenacin) At The 2018 CHEST Annual Meeting

Additional Analyses of Phase 3 Program Data Highlight Efficacy Advantages for 175 mcg/day of YUPELRI in Key Patient Subgroups, Demonstrate Acceptable Cardiovascular Safety Profile

Theravance Biopharma And Mylan To Present New Data From Studies Of YUPELRI™ (revefenacin) At The 2018 CHEST Annual Meeting

Theravance Biopharma And Mylan To Present New Data From Studies Of YUPELRI™ (revefenacin) At The 2018 CHEST Annual Meeting

Presentations Highlight Data of YUPELRI Compared with Tiotropium in Subpopulation of COPD Patients with Suboptimal Peak Inspiratory Flow Rates, Report Additional Data from Pivotal Phase 3 Program in Patients with Moderate to Very Severe COPD

3 Small Biotech Stocks to Watch in the Fourth Quarter

3 Small Biotech Stocks to Watch in the Fourth Quarter

These are just a few of the names I expect to do well to close out 2018.

3 Small Biotechs on My Q4 Watch List

3 Small Biotechs on My Q4 Watch List

These are a few of the names I expect to do well to close out 2018.

Mylan Extends Commitment To Fight HIV/AIDS By Partnering With Atomo Diagnostics To Expand Access To HIV Self-Testing In Low- And Middle-Income Countries

Mylan Extends Commitment To Fight HIV/AIDS By Partnering With Atomo Diagnostics To Expand Access To HIV Self-Testing In Low- And Middle-Income Countries

HERTFORDSHIRE,  England and PITTSBURGH and SYDNEY, Sept. 24, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan And Biocon Announce Positive CHMP Opinion For Fulphila®, Biosimilar Pegfilgrastim

Mylan And Biocon Announce Positive CHMP Opinion For Fulphila®, Biosimilar Pegfilgrastim

HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, Sept. 21, 2018 /PRNewswire/ --   Mylan N.

Mylan Launches Authorized Generic Of Ampyra® Tablets

Mylan Launches Authorized Generic Of Ampyra® Tablets

- Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis -

Mylan And Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization For Hulio®, Biosimilar Adalimumab

Mylan And Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization For Hulio®, Biosimilar Adalimumab

HERTFORDSHIRE, England and PITTSBURGH and TOKYO, Sept. 20, 2018 /PRNewswire/ --  Mylan N.

Theravance Biopharma And Mylan Report New Data From Phase 3 Studies Of YUPELRI™ (revefenacin) In Oral Presentation At The European Respiratory Society International Congress

Theravance Biopharma And Mylan Report New Data From Phase 3 Studies Of YUPELRI™ (revefenacin) In Oral Presentation At The European Respiratory Society International Congress

Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®)

Mylan Adds To Cardiovascular Portfolio With Launch Of First Generic Of Brevibloc® Injection In Single-Dose Bags

Mylan Adds To Cardiovascular Portfolio With Launch Of First Generic Of Brevibloc® Injection In Single-Dose Bags

- Esmolol Hydrochloride in Sodium Chloride Injection is used to control heart rate -

Theravance Biopharma And Mylan To Report New Data From Phase 3 Studies Of YUPELRI™ (revefenacin) In Oral Presentation At European Respiratory Society International Congress 2018

Theravance Biopharma And Mylan To Report New Data From Phase 3 Studies Of YUPELRI™ (revefenacin) In Oral Presentation At European Respiratory Society International Congress 2018

Presentation to Highlight COPD Exacerbation Rates Observed in Phase 3 Program of YUPELRI in Patients with Moderate to Very Severe COPD

Teva Notches Win With FDA Approval of Generic EpiPen

Teva Notches Win With FDA Approval of Generic EpiPen

The regulatory agency has authorized the sale of the drugmaker's generic version of Mylan's EpiPen.

Mylan Launches First Generic For Adcirca® Tablets

Mylan Launches First Generic For Adcirca® Tablets

- Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability -

This Market Isn't Weak, It's Just Tired

The market needs a pullback.

Stocks End Flat Amid Rising U.S.-China Trade Tensions; Disney, Tesla Slip

Stocks End Flat Amid Rising U.S.-China Trade Tensions; Disney, Tesla Slip

Stocks ended mixed on Wednesday as a push from strong corporate earnings is muted by continued trade tensions between the U.S. and China.

EpiPen Maker Mylan to Explore Options, Shares Sink

EpiPen Maker Mylan to Explore Options, Shares Sink

The drugmaker 's board said the U.S. public markets 'continue to underappreciate and undervalue' the company's diversified business.

TheStreet Quant Rating: C (Hold)